Kutshanje, iNational Medical Products Administration (NMPA) ivumile uphawu olutsha lwe-antibody-drug conjugate (ADC) Disitamab vedotin yokunyanga izigulane zomhlaza wamabele zabantu abadala ezine-HER2-low expression engasuswayo okanye esasazekayo (IHC 1+ okanye IHC 2+/ISH-) kunye ne-liver metastases, ezazikhe zafumana ubuncinci unyango olunye lwe-systemic kwindawo ye-metastatic, okanye ziye zaphinda zabuyela kwimeko yazo ngexesha okanye ngaphakathi kweenyanga ezili-12 zokugqiba i-adjuvant chemotherapy.
Oku kubonisa uphawu lwesine oluvunyiweyo lweDisitamab vedotin eTshayina, kulandela ukuvunywa kwayo kwangaphambili komhlaza wesisu, urothelial carcinoma, kunye nomhlaza webele ophucukileyo we-HER2-positive kunye ne-metastases yesibindi.
Ubungqina beklinikhi obuxhasa olu phawu lutsha busekelwe kuvavanyo lweklinikhi lweSigaba sesiThathu olucwangcisiweyo, oluvulekileyo, olulawulwa ngokulinganayo, oluneendawo ezininzi (RC48-C012) olwenziwe eTshayina. Olu phononongo lubonise ukusebenza kakuhle kunye nokhuseleko lweDisitamab vedotin kunyango lwabantu abadala abanomhlaza wamabele abane-HER2-low expression engasuswayo okanye esasazekayo (IHC 1+ okanye IHC 2+/ISH-) kunye ne-liver metastases, ababekhe bafumana ubuncinane unyango olunye lwe-systemic kwindawo esasazekayo, okanye babephinde babuyela umva ngexesha okanye kwiinyanga ezili-12 emva kokugqiba i-chemotherapy ye-adjuvant.
Ukuba wena okanye ilungu losapho lwakho nijongene nolu xilongo kwaye ninqwenela ukufunda ngeendlela zonyango zamva nje, iSebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region lizinikele ekuboneleleni izigulane zehlabathi ngeenkonzo zonyango eziphambili kunye nonyango oluhambelana nemigangatho yamazwe ngamazwe. Iqela lethu linokukunceda ekufikeleleni kunyango oluphambili kunye nokunxibelelana neengcali eziphambili, ukuqinisekisa amava ezonyango angobuchwephesha, alula, kwaye akhethekileyo eTshayina.
**Nxibelelana nathi namhlanje ukuze uqale uhambo lwakho lokubuyela esiqhelweni kunye nokubonisana:**
- **Umnxeba okhawulezileyo:** 400-880-3716 (ufumaneka iiyure ezingama-24 ngosuku, iintsuku ezisixhenxe ngeveki)
- **WeChat:** 17801183037 (songeze ukuze sinxibelelane ngoko nangoko)
- **I-imeyile:**
- 100085_010@163.com
- myimmnet@163.com
Nokuba uphi na, iSebe leMicimbi yeHlabathi leSibhedlele se-Oncology saseBeijing South Region lisebenza njengebhulorho eqinileyo kuwe yokufikelela kwizibonelelo zonyango ezikumgangatho ophezulu ngaphesheya kwemida. Masisebenzisane ukuguqula uphuhliso lwezonyango oluphambili lube lithemba elitsha lobomi bakho.
Ixesha leposi: Matshi-24-2026